Search the Newsreel

OKYO Pharma chairman now holds 20.51% after buying 25,000 shares

OKYO Pharma's Chairman, Gabriele Cerrone, increased his stake in the company by purchasing 25,000 ordinary shares at $1.40 each, bringing his total holding through Panetta Partners Ltd to 10,851,416 shares, or 20.51% of the issued share capital. The clinical-stage biopharmaceutical company is developing therapies …

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference. Robert J. Dempsey, CEO, and Flavio Mantelli, MD, PhD, CMO, will present on Wednesday, July 22, 2026, at 12:30 PM ET. The company …

Tokyo Electron: Favorable Read-Across From Industry Value Chain (OTCMKTS:TOELY)

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans Proactive uses images sourced from Shutterstock OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, …

OKYO Pharma (Nasdaq: OKYO) highlights cash for NEPTUNE Phase 3

OKYO Pharma reported its Annual Report on Form 20-F, highlighting approximately $20.6 million in cash and cash equivalents by March 31, 2026, after raising $25 million during the fiscal year. This financial strength is intended to fully fund the NEPTUNE Phase 3 pivotal trial …

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma announced the filing of its annual report, highlighting a strengthened cash position of $20.6 million after a successful $22 million capital raise. This funding fully supports the completion of the NEPTUNE Phase 3 pivotal trial for its lead candidate, urcosimod, for neuropathic …

OKYO Plans Phase 3 Trial for About 111 Patients With Corneal Pain

OKYO Pharma has filed its Annual Report on Form 20-F, revealing a strengthened cash position of approximately $20.6 million. This funding is expected to fully support its FDA-agreed global Phase 3 NEPTUNE pivotal trial for urcosimod in neuropathic corneal pain. The NEPTUNE trial, scheduled …

Tokyo Plast Greenlights 1 New Subsidiary to Scale Stainless Steel Drinkware Retail Sales

Nikkei 225 Forecast: Tokyo Electron Strength Drives Market Rebound

Nikkei 225 Forecast: Tokyo Electron Rally Offsets SoftBank Losses

Nikkei 225 Forecast: Advantest and Tokyo Electron Lead Push Toward 70,000

Tokyo Plast FY26 Results: Revenue Rises 9.44%, Standalone Profit Up 6.46%

Tokyo Plast International Reports Q3FY26 Results with Revenue Decline and Net Loss

Taiwan charges Tokyo Electron in TSMC secrets theft case

Advantest Powers Past Tokyo Electron to ¥10 Trillion Market Cap

TOKYO BASEが一時ストップ安､不振の1Q決算を嫌気

Tokyo Plast International Ltd. Share Price Today | Tokyo Plast Intl Live NSE/BSE

東京一番フーズ (3067) : 株主優待・優待利回り [TOKYO ICHIBAN FOODS]